REGMEDXB
FROM CARE TO CURE

Highlights 2025

CEO's Foreword

RegMed XB's 2025 marked another year of strong progress and growing international visibility. Regenerative medicine continued as a key approach to addressing the rising burden of chronic diseases, supported by expanding collaborations and concrete translational advances.

At the national level, collaboration across the Life Sciences & Health ecosystem continued to deepen. Progress across Moonshot programs, the Pilot Factory, and Public-Private Partnership activities demonstrated the growing maturity of the regenerative medicine ecosystem. Support for valorization advanced through new Thematic Tech Transfer (TTT) program funding, complemented by continued collaboration with Health~Holland. A Memorandum of Understanding was signed with seven other National Growth Fund initiatives, strengthening alignment and synergy across programs.

International engagement was significantly strengthened throughout the year. High-level representation included a meeting with the King of the Netherlands in Osaka, alongside visits from Japanese partners that opened new collaborative pathways. Strategic international expansion was further reinforced through the signing of a collaboration agreement with France's Inserm. In addition, RegMed XB contributed keynote presentations at major international conferences and international missions to Boston, Osaka, and Bern, fostering global knowledge exchange and partnership development.

Organizational development also advanced with the opening of a new office in Leuven, further reinforcing cross-border collaboration between the Netherlands and Flanders. This milestone was reflected in the first cross-border RegMed XB Annual Conference, hosted in Leuven and bringing together national and international partners.

This Highlights report reflects the collective commitment and contributions of partners across academia, industry, health foundations, government, and the Life Science and Health (LSH) sector. Appreciation is extended to all partners and stakeholders for their trust, dedication, and continued collaboration in advancing regenerative medicine for patients.

Bernard Mulder

CEO, RegMed XB

Index

About RegMed XB

RegMed XB is a translational product development platform that brings together Dutch and Flemish public and private stakeholders to accelerate the development of innovative regenerative therapies. All made possible through a strong ecosystem of health foundations, academic, industrial, governmental and Life Science & Health (LSH) partners. Together we make the impossible possible.

The prevalence of chronic diseases worldwide is rapidly increasing. Regenerative Medicine (RM) aims to restore degenerated, diseased, or damaged tissues and organs, which contributes to increasing vital functioning of patients and reducing cost of healthcare.

Regenerative medicine holds the promise to cure many chronic conditions, restoring health rather than protracting decline. Improving the lives of millions and at the same time preventing lifelong, expensive care processes: cure instead of care.

At the moment we have the following Moonshots: Cardiovascular, Diabetes, Eye, Kidney and Osteoarthritis.

Health foundations and their related patient organizations champion each moonshot, putting patient impact at the heart. At RegMed XB translational infrastructure is provided through scientific, technological and business development.

The approach, that links all phases from research to the production of therapies, makes RegMed XB unique.

In the figure below the five pillars of RegMed XB:



In 2025, RegMed XB's focus to drive research excellence is again pushed to the next level, this time by hiring new team members.

"I believe in the transformative potential of regenerative medicine, not only to treat, but to truly restore health. RegMed XB's activities to accelerate this transition aligns closely with my personal motivation to create lasting, real-world impact for patients. I am finding energy in enabling innovation by connecting people, organizations, and disciplines.

Nick Beijer, Business Developer

"I'm driven by the potential of regenerative medicine to truly change patients' lives. Contributing to solutions that are not only innovative but also accessible and curative is deeply meaningful to me. Being part of RegMed XB's mission is a unique opportunity to bring together science, compassion, and collaboration in a way that has real-world impact."

Nabahats Coers, Project Manager

"In academic research, the sky is the limit and a plethora of regenerative solutions are developed all over the world. Yet this amazing science does not reach patients. Following a motorcycle accident, and an intensive ongoing 4-year recovery trajectory, I have been confronted with being a patient, this personal experience is the driving force to provide access to medicines that give people back their quality of life."

Isaak Decoene, Jr. Product Development Manager (Flanders)

Flemish Highlights

After Maastricht and Utrecht, the new RegMed XB Flanders workspace at Bio-Incubator 4, officially opened at September 4th, 2025 in Leuven

At the dynamic Arenberg Science Park at Flanders, knowledge institutes such as KU Leuven, the UZ Leuven, and important research centers, like Imec and VIB (Flemish Institute for Biotechnology) are established.

RegMed XB is based on the 3rd floor of Bio-Incubator 4, sharing the space with LinX, an ATMP development hub.

Looking back on an inspiring edition of Science for Health on November 4th, 2025 in Brussels

At Science for Health, RegMed XB Flanders made a visible impact through a booth hosted by Andromache Goethals and Isaak Decoene. In addition to on-site engagement, Andromache took the stage to position RegMed XB as a mature ATMP ecosystem, highlighting its role in linking biology, technology, and regional expertise to drive innovation.

Strengthening the RegMed XB Flemish–Dutch Advanced Therapy Medicinal Products (ATMPs) ecosystem

RegMed XB proudly contributes to ATMP XB, a €3.5 million Interreg-cofunded initiative led by Biovia, aimed at reinforcing the cross-border ecosystem for ATMPs in Flanders and the South of the Netherlands. Supported by the European Union through Interreg Vlaanderen-Nederland.

.

In January the Belgian Health Care Knowledge Centre (KCE) published a report on ATMP development, providing evidence-based recommendations to address these barriers.

In this report, RegMed XB is highlighted as a best-practice example of international collaboration. By enabling academia to share expertise in regenerative medicine and offering tailored, government funded consultation, RegMed XB supports the definition of robust target product profiles and facilitates the translation of ATMPs into clinical practice within the Flanders healthcare system.

Valorization

RegMed XB collaborated with the Dutch CardioVascular Alliance (DCVA) and F!RST Fund (BGV) in a Thematic Tech Transfer (TTT) program to stimulate the clinical translation of promising projects within regenerative medicine and cardiovascular disease.
The TTT-program is a subsidy tool that exists of two pillars, the first is a non-dilutive voucher of up to €25.000 for entrepreneurial researchers and the second is a pre-seed investment fund for promising spin-offs. In 2025, the previous TTT program was officially concluded, and a new program has been awarded by the RVO. This means that €10 million has been mobilized to continue the TTT activities until 2030.

Results (2020-2025)
During the whole program, a total of 42 vouchers have been awarded.

These vouchers enabled researchers to take essential steps towards a viable and investable startup. So far, thirteen spinoffs have been founded building on these voucher projects and we are excited to see what the future holds for all voucher laureates. F!RST Fund has invested in seven promising Startups.

New program (2025-2030)
The new TTT program builds on the network and knowledge that has been developed over the last years. This edition, the program is expanded by active participations of four health foundations: Dutch Kidney Foundation, Dutch Heart Foundation, Dutch Brain Foundation, and the Dutch Diabetes Fund. This collaboration will expand the scouting capacity, resulting in more high-quality projects that come to the attention of the TTT program.

For academic researchers and healthcare innovators interested in valorization, entrepreneurship, and accelerating from lab to patient.
RegMed XB invites you to the next Dutch CardioVascular Alliance & RegMed XB Community Event.

📅 **Date: 12 February 2026**
📍 **Location: Grand Hotel Karel V, Utrecht**

14:30-15:00
Walk in & registration

15:00-16:45
Plenary program including two keynotes by academic founders on their entrepreneurial journey:
Dr. René van Es, founder & CSO, Cordys Analytics and Associate Professor, UMC Utrecht & Dr. Stefan Braam, founder & CTO, Ncardia and Cellistic
Pitches from promising startup teams

16:45-17:00
Farewell outgoing DCVA managing director (Prof. Jolien Roos-Hesselink) and welcome of the new DCVA managing director (Prof. Eric Boersma)

17:00-18:00
Networking drinks

RESERVE A SPOT

Examples of entrepreneurial teams RegMed XB supported

In 2020, the Dutch Cardiovascular Alliance (DCVA) and RegMed XB launched a spin-off funding initiative together with the Netherlands Enterprise Agency (RVO) and BioGeneration Ventures (BGV), the registered fund manager of the associated FIRST Fund. From the many vouchers awarded, RegMed XB selected four projects and conducted interviews in 2025 with entrepreneurs supported by RegMed XB and DCVA within the Thematic Technology Transfer (TTT) voucher programme. Read the highlighted interviews from last year.

PHLOX THERAPEUTICS
Develops RNA-based therapies for genetic cardiomyopathies.
>> read more

HELLO R&D
Sets out to eliminate liver toxicity.
>> read more

XS INNOVATIONS
Brings a new standard to dialysis care.
>> read more

SBMATRICES
Develops a synthetic, animal-free alternative to Matrigel.
>> read more

RegMed XB is bringing science and entrepreneurship together by:

- Organizing (Valorization) Community events
- Educating researchers and policy makers
- Supporting researchers in commercializing their inventions

The Impact Officers actively scouting for high-impact research with spinoff potential in the field of chronic diseases and guide research teams through the world of technology transfer and academic entrepreneurship.

Moonshot Updates

KIDNEY
MOONSHOT

The Kidney Moonshot aims to create functional kidney tissue using mini kidneys or organoids, grown from cells obtained from kidney tissue or urine.

Mimetas and the UMC Utrecht work together with the Kidney Foundation and RegMed XB in a project within the Kidney moonshot, focusing on the development of an advanced tubuloid-on-a-chip model to study kidney physiology and pathophysiology.

This animal free model is attractive to understand kidney function and the interaction between the cells of the kidney tubule and the nearby blood vessels.

Using advanced cell culture technologies, the team has successfully grown donor-derived kidney tubuloids on a chip that closely replicate human, mostly distal tubular, functions. This allows precise assessment of water and sodium transport, as well as responses to drugs and toxins, supporting drug discovery and toxicity testing.

Furthermore, the team is collaborating with Mimetas to further advance the model toward commercialization.

Looking ahead, integration of regenerative medicine interventions into this platform is planned for 2026, in collaboration with stakeholders.

Publication: DOI: 10.34067/KID.0000000992

CARDIOVASCULAR
MOONSHOT

The Cardiovascular Moonshot is focused on developing and validating an advanced ex vivo heart perfusion bioreactor as an initial milestone on the Moonshot roadmap.

The current project, funded by the Dutch Heart Foundation and the Dutch Ministry of Economic Affairs by means of the public-private partnership allowance made available by the Top Sector Life Sciences & Health, focuses on extension of donor heart condition to consistently 24 hours, and up to 48h, enabling evaluation of future regenerative therapies.

In 2025, optimization of the perfusion conditions was performed by comparing standard and immune cell–depleted perfusates and assessment of effects on cardiac function, tissue damage, and endothelial integrity. Temperature modulation studies are also evaluating vascular barrier preservation during prolonged perfusion. Ongoing work includes the further validation of biomarkers of endothelial dysfunction, cardiomyocyte stress, inflammation, and coagulation, supporting tissue assessment and therapeutic decision-making.

Technical advancements include refinement of the Afterload Module, alongside optimization of ex vivo mouse heart culture protocols, including electrical pacing and perfusate composition.

Publication: DOI: 10.1097/MAT.0000000000002419

DIABETES
MOONSHOT

The goal of the Diabetes Moonshot is to advance the cure for diabetes Type I by producing stem cell-derived insulin secreting cells and a proper delivery device.

A short- and long-term roadmap has been agreed upon with full support from all the involved partners. A major scientific milestone was recently achieved at Leiden University Medical Center (LUMC) with the development of a novel purification method for stem cell–derived insulin-producing islets. This approach significantly improves product purity, reduces unwanted cell types, and strengthens both the safety profile and regulatory acceptability of the therapy.

In parallel, development of the delivery device has advanced substantially. An open-structure device design has been selected, and extensive safety testing is underway by an external private partner. These preclinical studies are expected to generate robust safety data for the regulatory dossier, with final reports expected by Q1 2026.

Necstgen, a RegMed XB Pilot Factory line, supports the GMP transition and scale-up of stem cell–derived insulin-producing cell production.

In 2026, efforts will be fully focused to preparation activities to enable initiation of a first clinical trial as a sentinel device.

Publication: DOI: 10.1126/scitranslmed.adl4390

OSTEOARTHRITIS
MOONSHOT

The Osteoarthritis (OA) Moonshot focuses on the development of an off-the-shelf, resorbable (partly cellularized) implant for large and deep osteochondral defects in the 'young' patient (under 60 years of age). This novel therapeutic approach is positioned as a regenerative alternative to allografts and represents the first step in a broader vision toward creating a bio-artificial joint.

In 2025, a strategic roadmap was completed, defining the phased development pathway for a tissue-engineered advanced therapy medicinal product (ATMP) targeting deep osteochondral defects, with the ultimate goal of achieving a fully functional, living joint replacement. As part of this initiative, a comprehensive Target Product Profile (TPP) is scheduled for finalization in 2026.

The program starts with the development of a tissue-engineered ATMP that integrates cellular, and biomaterial components to restore the osteochondral unit of the knee joint. This includes the scaled production of iPS derived cartilage and cells. A diverse consortium of academic and industrial partners is actively engaged, with RegMed XB's Pilot Factory infrastructure playing an increasingly prominent role: ICAT, NecstGen, ReGEN Biomedical, and Smart BioMaterials Center (SBMC) are progressively contributing to process development, scale-up, and manufacturing readiness. This initiative exemplifies a multidisciplinary, collaborative approach, aimed at redefining the treatment paradigm for joint disorders and advancing a new generation of regenerative joint therapies.

In 2025, the Flanders OA team achieved the GMP production of primary human articular cartilage cells as building blocks for large osteochondral implants. By 2026, the program will advance to GMP manufacturing of cartilage patches derived from primary human articular chondrocytes, alongside validation of fully automated, large-scale production of progenitor derived cartilage and bone forming organoids. This milestone is intended to culminate in the biofabrication of the first human-scale, 3D-printed, living hemi-joint implant.

EYE
MOONSHOT

For patients who need a cornea transplant, the RegMed XB Eye Moonshot is developing a vision-saving regenerative therapy. The Eye Moonshot was launched in 2024 by RegMed XB together with the Dutch Oogfonds and researchers in the Netherlands and Flanders.

The Moonshot aims to develop a living tissue composed of stem cell–derived corneal endothelial cells combined with a biomaterial membrane. By manufacturing a highly standardized, off-the-shelf product, patients currently on transplantation waitlists could receive a vision-saving therapy that is otherwise unavailable.

In 2025, researchers developed a highly efficient method for producing corneal endothelial cells, including a functional quality control assay.

Development of the biomaterial membrane is progressing, with production scheduled to transfer to the Smart BioMaterials Center (SBMC) Pilot Factory in early 2026. Key next steps include evaluating cell–membrane interactions and generating pre-clinical data on the safety and efficacy of this novel therapy.

Publication: DOI: 10.3390/biom15081139

Conference Highlights

RegMed XB colleagues actively contribute to national and international conferences, showcasing the translational work that RegMed XB delivers across the health and life sciences ecosystem.

Below are selected highlights illustrating the engagement and collaboration.

BOOTH AT INNOVATION FOR HEALTH
On April 3rd in Rotterdam, the RegMed XB Pilot Factory, Biotech Booster, Oncode Accelerator, and RegMed XB jointly participated at Innovation for Health, a leading Health & Life Sciences event. Together, they were represented at the Utrecht Science Park booth.

Pilot Factory Updates

The RegMed XB Pilot Factory is one of the largest international infrastructures for the production of regenerative products. The shared mission is to accelerate the development of new solutions for chronic diseases and to bring affordable Regenerative Medicine (RM) therapies to patients.

The RegMed XB Pilot Factory (a collaborative powerhouse and partnership of five expert centers) provides:

- Access to state-of-the-art facilities
- Embedded technical and regulatory expertise
- A platform to accelerate translation and manufacturing

ReGEN Biomedical
Revolutionizing the production of functional tissues

REGEN BIOMEDICAL IN RESEARCH CONSORTIA

In 2025 ReGEN Biomedical joined two successful consortia who got granted research funding. ReGEN Biomedical will continue to develop expertise in the NEOLIVER and micro2MACRO projects.
>> read more

SBMC OPENS CLEANROOMS IN EINDHOVEN

In 2025, SBMC at the High Tech Campus Eindhoven opened four brand-new cleanrooms, together covering 400 m². Ranging from small to large, these cleanrooms are available to organizations supporting GMP production pipelines.
>> explore in 360 degree

SBMC BIOMATERIALS HACKATON 2025

In February 2025 SBMC organized the Biomaterials Hackaton for biomaterials researchers to work on challenges related to gaining impact with biomaterials.
>> read more

SBMC AS CONSORTIUM PARTNER

In 2025 SBMC joined research consortia in promising highly innovative projects, as e.g. ATMP-XB and HYBROS.
>> read more

NECSTGEN AS PROJECTPARTNER

As part of the IPCEI Med4Health program NecstGen joined a strong consortium to work on pioneering cost-effective production methods for several treatments.
>> read more

ICAT OOC MASTERCLASS

Together with AZAR innovations, ICAT organized a 3-day masterclass on Organ-on-a-Chip, with hands-on experience and expert insights.
>> read more

PILOT FACTORY SHARED BOOTH AT TERMIS

At TERMIS-EU 2025 on May 19-22, in Freiburg, Germany, the RegMed XB Pilot Factory was represented by its Pilot Lines to connect with the regenerative medicine community
>> read more

PILOT FACTORY DELEGATION AT BIOFABRICATION 2025 IN WARSAW

September 14-17, in Warsaw, Poland, a delegation of the RegMed XB Pilot Factory represented some of the Pilot Lines during this leading international stage for cutting-edge research and innovation in biofabrication and regenerative medicine.
>> read more

Public-Private Partnership (PPS) Subsidy program

In October 2024, RegMed XB was selected by Health~Holland as one of the awarded programs. The resulting three-year Public–Private Partnership (PPP) subsidy program, titled Regenerative Medicine Translational Synergy, includes reserved funding of €2 million in 2025, with equivalent conditional allocations for 2026 and 2027.

About the Program
The program supports translational public–private partnership projects in regenerative medicine, enabling consortia of companies and research institutions to secure funding for accelerating breakthrough innovations in the Life Sciences & Health sector. Through this initiative, partners collaboratively select and advance PPP projects supported by Health~Holland funding. RegMed XB focuses on regenerative medicine, a rapidly advancing field with the potential to restore or replace damaged tissues and organs. In collaboration with public and private partners, RegMed XB is driving ambitious moonshot programs to address major unmet patient needs. Beyond transforming healthcare, the initiative contributes to economic growth through innovation and cross-sector collaboration.

In 2025, the first projects completed the full 2025 PPS process. In addition, RegMed XB was also awarded funding for the 2026 PPS.

Program Group
RegMed XB; the Dutch Diabetes Research Foundation; the Dutch Kidney Foundation; the Dutch Heart Foundation; the Eye Foundation; Eindhoven University of Technology (TU/e); UMC Utrecht; Leiden University Medical Center (LUMC); Maastricht University; and HCM Medical.



NL Health~Holland

€10 Million Subsidy for Regenerative Medicine Projects

In November, the second tender of the Subsidy for Regenerative Medicine has been announced by the Netherlands Enterprise Agency (RVO). This subsidy scheme stimulates public-private research partnerships for the development of regenerative medicine products.

A Public-Private funding opportunity for Regenerative Medicine Research
The Dutch government has committed €30 million to foster innovation in regenerative medicine through the Subsidy scheme for regenerative medicine Research Projects/Subsidieregeling Regeneratief Geneeskundige Onderzoeksprojecten (SRGO). This initiative is designed to promote collaboration between SMEs in the biomedical sector and research institutions, with the aim of accelerating the development of regenerative medicine solutions.

In the announced second tender, €10 million of the overall €30 million budget will be available. Based on insights from the previous tender, eligibility criteria for Small and Medium sized Enterprises (SMEs) are alleviated, and the funding conditions have been amended.



>> Visit the RVO website for more information.

The SRGO is co-funded by the Ministry of Economic Affairs and the Ministry of Health, Welfare, and Sport, and is managed by the Netherlands Enterprise Agency (RVO). The total €30 million will be allocated in stages through three separate tenders. The first tender was from July 1st until December 2nd, 2024.

National Collaborations

Building on earlier collaboration, RegMed XB took an important next step in strengthening the Dutch Life Sciences & Health (LSH) ecosystem. Following the cooperation agreement signed last year with Biotech Booster and Oncode Accelerator, RegMed XB formalized its broader commitment by signing a Memorandum of Understanding (MoU) with in total seven initiatives supported by the National Growth Fund (Nationaal Groeifonds).

Growing together in Life Sciences & Health
As of 2 December 2025, eight National Growth Fund–funded initiatives are officially joining forces to accelerate innovation, translation, and sustainable economic growth in Life Sciences & Health, firmly anchored in societal impact for The Netherlands.

This joint commitment marks a transition from aligned ambitions to coordinated action. By strengthening connections across programmes, infrastructures, and expertise, the initiatives aim to reduce fragmentation, enhance knowledge exchange, and accelerate the journey from scientific discovery to real-world application. For RegMed XB, the collaboration reinforces its mission to advance regenerative medicine through shared infrastructure, complementary expertise, and collective impact within a strong national ecosystem.

Alongside RegMed XB, the MoU was signed by:

- Biotech Booster
- Health-RI
- Holomicrobiome Institute
- NXTGEN Hightech
- Ombion
- Oncode Accelerator
- PharmaNL



biotech booster | REGMEDXB FROM CARE TO CURE | Oncode Accelerator

Aan de voorzitter van de Tweede Kamer der Staten-Generaal

Utrecht, 17 maart 2025

Betreft: amendement bij de Wet actualisering lichaamsmateriaalwetgeving

Geachte voorzitter,

[illegible]

Met vriendelijke groet,

Nettie Buitelaar, Biotech Booster

Bernard Mulder, RegMed XB

Friso Smit, Oncode Accelerator

Joint Action on Dutch governmental amendment

In April 2025, RegMed XB, together with Biotech Booster, Oncode Accelerator, and several health foundations, acted swiftly. Supported by the BPRA Public Affairs office, they responded to a proposed parliamentary amendment affecting advanced therapy medicinal products (ATMPs). The ‘Updating legislation on human body materials’ in Dutch: >> Wet actualisering lichaamsmateriaalwetgeving (36.516)

The amendment aimed to remove the existing exemption to the profit distribution ban for institutions that obtain human body materials for further processing into medicinal products. In a joint letter to parliamentary spokespersons, the parties warned that, despite good intentions, the amendment could hinder the development and accessibility of innovative ATMP treatments, ultimately impacting patients.

New RegMedXB.com website and phone number

In November 2025, RegMed XB launched a new website with a fresh design, hosted on a stable and secure new platform. The website and digital collaboration environment are hosted by Maastricht University, one of RegMed XB’s consortium partners.

This transition strengthens the security, continuity, and future readiness of RegMed XB’s digital infrastructure. Data ownership remains fully with RegMed XB, and the organizations identity and independence are unchanged. Partners continue to collaborate with RegMed XB via Microsoft Teams, now operating on a professional, secure hosting environment, including a telephone number.



International Collaborations

Curious? Click on the link for the report: lnkd.in/ezyG96BK

April: Innovation Mission Regenerative Medicine, 6-11 April in Boston (Massachusetts) & Manchester (New Hampshire) United States of America
But where do the opportunities lie? The answer is explored in a Opportunity report: Massachusetts-The Netherlands, in partnership with Netherlands Innovation Network in Boston, Health~Holland International, and RegMed XB, with insights from NL-USA consulting experts in Regenerative Medicine.

May: Nakanoshima Qross, Osaka
Bernard Mulder had the honour of joining His Majesty King Willem-Alexander of the Kingdom of the Netherlands, Prof. Yoshiki Sawa, Chairman of Nakanoshima Qross, and H.E. Ms. Reinette Klever, former Minister for Foreign Trade and Development Cooperation of The Netherlands.

June: Life Science & Health Mission to Japan, 22-28 June. RegMed XB and the collaboration between Nakanoshima Qross was represented during a Regenerative Medicine symposium, and the World Expo 2025 in Osaka. The mission and symposium are some of the key milestone in the ongoing collaboration initiated by the Memorandum of Understanding (MoU) signed in October 2024 between RegMed XB and Nakanoshima Qross.



Logo's are displayed at the satellite offices: Osaka, Japan & Utrecht, the Netherlands.

July: Memorandum of Understanding with Inserm RegMed XB and Inserm signed a Memorandum of Understanding (MoU) at the French Residence in The Hague. The MoU was signed by Didier Samuel, Chairman and CEO of Inserm.

Inserm is France's national research institute for health and medical research, renowned for its state-of-the-art technologies with strong potential for advancing regenerative medicine. This partnership reflects the shared ambition of France and the Netherlands to develop innovative and sustainable solutions that benefit patients while strengthening Europe's strategic autonomy in health.

September: Economic Mission to Switzerland From 9 to 11 September, RegMed XB participated in an economic mission to Switzerland together with the National Growth Fund initiatives Biotech Booster and Oncode Accelerator.
In Basel and Bern, the delegation focused on the development and manufacturing of promising innovative therapies, as well as human-based test models.

The official opening of the Nakanoshima Qross Satellite Office in Utrecht.

October: Japan–Netherlands Mission in the Netherlands
On 15–16 October 2025, RegMed XB hosted a high-level delegation from Nakanoshima Qross (Japan) as part of the Japan–Netherlands mission. Over two days, the delegation visited Leiden, Utrecht, Eindhoven, and Maastricht, engaging with centres of scientific excellence, Pilot Lines, regional development agencies, science parks, and other key stakeholders.

Annual Conference

The 3rd Annual Conference on Regenerative Medicine, hosted by RegMed XB, gathered and attracted nearly 200 attendees.
Held on June 18th and 19th in Leuven, Belgium, the event provided a platform for professionals across the entire spectrum of regenerative medicine, from innovative start-ups, researchers, and industry experts to government representatives, health foundations, and visionaries in the field.

The underlying theme of the conference was: Beyond Borders. It was the first time for the Conversation Starter application and that RegMed XB offered a space for exhibitors.

REGMED XB 3RD ANNUAL CONFERENCE 2025
JUNE, 18TH AND 19TH JUNE 2025 AT KU LEUVEN

Watch the after movie

Thanks to all Partners

Academic partners

Ghent University
KU Leuven
Leids Universitair Medisch Centrum
Maastricht University
Maastricht UMC+
TU/e Eindhoven University of Technology
University of Antwerp
UMC Utrecht
Utrecht University
VUB Vrije Universiteit Brussel
VIB

Health Foundations

Diabetes Fonds
don We just care for cure
Hartstichting
NIER Stichting
Oogfonds
ReumaNederland
Hersen Stichting

Pilot lines

ICAT Innovation Center for Advanced Therapies
Leids Universitair Medisch Centrum
NecstGen
ReGEN Biomedical
SBMC Smart BioMaterials Consortium

Industrial partners

300MICRONS
Flexible 3D Cell Culture Solutions

Access2bone

AXION BIOSYSTEMS

CiMaas
A better cure for cancer

Coagulation Profile

ETB-BISLIFE

eurobiogendx

FUJIFILM VISUALSONICS

HCM Medical

interflow

Kuros Biosciences

MIMETAS

Ncardia
Stem cell experts

NTrans Technologies

QUALITY ASSISTANCE
Contract Research Organisation

scannexus

SCINUS CELL EXPANSION

SINGLE CELL DISCOVERIES

Starfish INNOVATIONS

STENTIT

SupraPolix

U-CyTech biosciences

veldlaser

XELTIS

Governmental partners

Flanders
State of the Art

NL Health~Holland

provincie limburg

Provincie Noord-Brabant

PROVINCIE UTRECHT

provincie Zuid-Holland

Ministerie van Economische Zaken

Ministerie van Volksgezondheid, Welzijn en Sport

Ministerie van Onderwijs, Cultuur en Wetenschap

Netherlands Enterprise Agency

Nationaal Groeifonds

Life Science & Health partners